Antiarrhythmic propafenone: improving patient outcomes.
Propafenone which is distributed as Rythmol by Knoll Pharmaceuticals (Whippany, New Jersey) is a class IC antiarrhythmic agent approved by the Food and Drug Administration (FDA) for the treatment of patients with life-threatening, malignant ventricular arrhythmias. It is still under investigation for use in patients with non-malignant ventricular arrhythmias, supraventricular arrhythmias, and atrial fibrillation or flutter. This author describes the pharmacokinetics and nurse's role for improving outcomes for patients on propafenone.
L A
LA
Brzozowski
D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology; D003422:Critical Care; D016903:Drug Monitoring; D006352:Heart Ventricles; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D011405:Propafenone / Q000494:pharmacology / Q000627:therapeutic use*
D011405:Propafenone